The patent will run to Sep 2010 if MDCO gets a 6-month pediatric extension. The salient point, however, is that someone could already have submitted an Angiomax ANDA with the intention of launching when the patent expires. As mentioned in my prior post, the FDA does not disclose ANDA's submitted under P-III (i.e. those with no patent challenge).
Market Data 
Markets 
AI
